Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial | Zendy

Stefan Bielack | Zendy; Sigbjørn Smeland | Zendy; Jeremy Whelan | Zendy; Neyssa Marina | Zendy; Gordana Jovic | Zendy; Jane Hook | Zendy; Mark Krailo | Zendy; Mark C. Gebhardt | Zendy; Zsuzsanna Pápai | Zendy; James S. Meyer | Zendy; Helen Nadel | Zendy; R. Lor Randall | Zendy; Claudia Deffenbaugh | Zendy; Rajaram Nagarajan | Zendy; Bernadette Brennan | Zendy; G. Douglas Letson | Zendy; Lisa A. Teot | Zendy; Allen M. Goorin | Zendy; Daniel Baumhoer | Zendy; Leo Kager | Zendy; Mathias Werner | Zendy; Ching C. Lau | Zendy; Kirsten Sundby Hall | Zendy; Hans Gelderblom | Zendy; Paul A. Meyers | Zendy; Richard Görlick | Zendy; Rein﻿hard Windhager | Zendy; K. Helmke | Zendy; Mikael Eriksson | Zendy; Peter M. Hoogerbrugge | Zendy; Paula J. Schomberg | Zendy; PerUlf Tunn | Zendy; Thomas Kühne | Zendy; Heribert Jürgens | Zendy; Henk van den Berg | Zendy; Tom Böhling | Zendy; Susan Picton | Zendy; Marleen Renard | Zendy; Peter Reichardt | Zendy; Joachim Gerß | Zendy; Trude ButterfaßBahloul | Zendy; Carol D. Morris | Zendy; Pancras C.W. Hogendoorn | Zendy; Beatrice Seddon | Zendy; Gabriele Calaminus | Zendy; Maria Michelagnoli | Zendy; Catharina Dhooge | Zendy; Matthew R. Sydes | Zendy; Mark L. Bernstein | Zendy

Open Access

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Author(s) -

Stefan Bielack,

Sigbjørn Smeland,

Jeremy Whelan,

Neyssa Marina,

Gordana Jovic,

Jane Hook,

Mark Krailo,

Mark C. Gebhardt,

Zsuzsanna Pápai,

James S. Meyer,

Helen Nadel,

R. Lor Randall,

Claudia Deffenbaugh,

Rajaram Nagarajan,

Bernadette Brennan,

G. Douglas Letson,

Lisa A. Teot,

Allen M. Goorin,

Daniel Baumhoer,

Leo Kager,

Mathias Werner,

Ching C. Lau,

Kirsten Sundby Hall,

Hans Gelderblom,

Paul A. Meyers,

Richard Görlick,

Reinhard Windhager,

K. Helmke,

Mikael Eriksson,

Peter M. Hoogerbrugge,

Paula J. Schomberg,

PerUlf Tunn,

Thomas Kühne,

Heribert Jürgens,

Henk van den Berg,

Tom Böhling,

Susan Picton,

Marleen Renard,

Peter Reichardt,

Joachim Gerß,

Trude ButterfaßBahloul,

Carol D. Morris,

Pancras C.W. Hogendoorn,

Beatrice Seddon,

Gabriele Calaminus,

Maria Michelagnoli,

Catharina Dhooge,

Matthew R. Sydes,

Mark L. Bernstein

Publication year - 2015

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2014.60.0734

Subject(s) - medicine , chemotherapy , surgery , methotrexate , toxicity , cisplatin , osteosarcoma , doxorubicin , gastroenterology , urology , pathology

EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research